

References for the brochure: THE BENEFITS OF CITRASATE®

1. Coresh J. Update on the Burden of CKD. J Am Soc Nephrol. 2017

2. de Sequera P, et al. Advantages of the use of citrate over acetate as a stabilizer in hemodialysis fluid: A randomized ABC-treat study. Nefrologia (Engl Ed). 2021

3. Kohn OF, et al. Dual-concentrate bicarbonate-based hemodialysis: know your buffers. Artif Organs. 2012

4. Dhondup T, et al. Electrolyte and Acid-Base Disorders in Chronic Kidney Disease and End-Stage Kidney Failure. Blood Purif. 2017

5. Pérez-García R, et al. Citrate dialysate does not induce oxidative stress or inflammation in vitro as compared to acetate dialysate. Nefrologia. 2017

6. Matsuyama K, et al. Acetate-free blood purification can impact improved nutritional status in hemodialysis patients. J Artif Organs. 2011

7. Pérez-García R, et al. Hypomagnesaemia in haemodialysis is associated with increased mortality risk: its relationship with dialysis fluid. Nefrologia (Engl Ed). 2020

8. Weiss w, et al. SP681, Decrease of inflammation and bleeding times in chronic dialysis patients by long-term use of citrate-enriched dialysate. nephrology dialysis transplantation. 2017

9. Kuragano T, et al. Effects of acetate-free citrate-containing dialysate on metabolic acidosis, anemia, and malnutrition in hemodialysis patients. Artif Organs. 2012

10. Rezende LR, et al. Metabolic acidosis in hemodialysis patients: a review. J Bras Nefrol. 2017

11. Panichi V, et al. Post-dilution on line haemodiafiltration with citrate dialysate: first clinical experience in chronic dialysis patients. Scientific World Journal. 2013

12. Tentori F, et al. Association of dialysate bicarbonate concentration with mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2013

13. de Mutsert R, et al. Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrol Dial Transplant. 2008

14. Pizzarelli F, et al. Citrate high volume on-line hemodiafiltration modulates serum Interleukin-6 and Klotho levels: the multicenter randomized controlled study "Hephaestus". J Nephrol. 2021



15. Paim BA, et al. Oxidative stress in hypercholesterolemic LDL (low-density lipoprotein) receptor knockout mice is associated with low content of mitochondrial NADP-linked substrates and is partially reversed by citrate replacement. *Free Radic Biol Med.* 2008
16. Flythe JE, et al. Association of mortality risk with various definitions of intradialytic hypotension. *J Am Soc Nephrol.* 2015
17. Shoji T, et al. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. *Kidney Int.* 2004
18. Belardi JA, et al. Anticoagulation with heparin The art of simplicity even in patients on dialysis. *Catheter Cardiovasc Interv.* 2017
19. Fischer KG. Essentials of anticoagulation in hemodialysis. *Hemodial Int.* 2007
20. Davenport A. What are the options for anticoagulation needs in dialysis for patients with heparin-induced thrombocytopenia? *Semin Dial.* 2011
21. David I. Ortiz-Melo ECK. Methods of Hemodialysis Anticoagulation, Handbook of dialysis therapy 2017.
22. Sands JJ, et al. Effects of citrate acid concentrate (citrasate®) on heparin N requirements and hemodialysis adequacy: a multicenter, prospective noninferiority trial. *Blood Purif.* 2012
23. Vandenbosch I, et al. Strategies for asymmetrical triacetate dialyser heparin-free effective haemodialysis: the SAFE study. *Clin Kidney J.* 2021
24. Kossmann, Callan, Ahmad. Fifty-five Percent Heparin Reduction is Safe with Citrate Dialysate in Chronic Dialysis Patients. ASN's 39th Annual Renal Week Meeting
25. Roland E. Winkler PA, Wolfgang Paetow, Grit Waitz and Hartmut Wolf. Reduction of Heparin and Oxidative Potential by Means of Citrasate® in High-Flux Dialysis (HFD) and Online Hemodiafiltration (oHDF) in Pre and Postdilution. <https://www.intechopen.com/chapters/43095>. 2012
26. Kossmann RJ, et al. Increased efficiency of hemodialysis with citrate dialysate: a prospective controlled study. *Clin J Am Soc Nephrol.* 2009
27. Molina Nuñez M, et al. Citrate versus acetate-based dialysate in on-line haemodiafiltration. A prospective cross-over study. *Blood Purif.* 2015
28. Portolés J, et al. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. *Front Med (Lausanne).* 2021
29. Ma J, et al. Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study. *Atherosclerosis Risk in Communities Study. J Clin Epidemiol.* 1995
30. Gussak I, et al. Sudden cardiac death in nephrology: focus on acquired long QT syndrome. *Nephrol Dial Transplant.* 2007

31. Del Giorno R, et al. Consequences of Supraphysiological Dialysate Magnesium on Arterial Stiffness, Hemodynamic Profile, and Endothelial Function in Hemodialysis: A Randomized Crossover Study Followed by a Non-Controlled Follow-Up Phase. *Adv Ther.* 2020
32. Bressendorff I, et al. The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects with End Stage Kidney Disease: A Randomized, Controlled Clinical Trial. *Clin J Am Soc Nephrol.* 2018
33. Sakaguchi Y, et al. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. *Kidney Int.* 2014
34. He K, et al. Magnesium intake and incidence of metabolic syndrome among young adults. *Circulation.* 2006
35. Okazaki H, et al. Significant positive relationship between serum magnesium and muscle quality in maintenance hemodialysis patients. *Magnes Res.* 2013
36. Yu L, et al. Association between Serum Magnesium and Erythropoietin Responsiveness in Hemodialysis Patients: A Cross-Sectional Study. *Kidney Blood Press Res.* 2019
37. Vida C, et al. A high magnesium concentration in citrate dialysate prevents oxidative stress and damage in human monocytes in vitro. *Clin Kidney J.* 2021
38. Monardo P, et al. Updates on hemodialysis techniques with a common denominator: The personalization of the dialytic therapy. *Semin Dial.* 2021